Ovarian cancer nursing: NCLEX reference guide

Ovarian cancer is the fifth leading cause of cancer death in women in the United States and the deadliest gynecologic malignancy. It earns the “silent killer” label not because symptoms are absent, but because they are vague enough — bloating, pelvic pressure, early satiety — that patients and providers frequently attribute them to benign causes. By the time diagnosis is confirmed, roughly 75% of women present with Stage III or Stage IV disease, making surgical and systemic nursing care both high-acuity and high-stakes.

For NCLEX candidates, ovarian cancer is a fertile source of pharmacology, oncologic nursing, genetics, and perioperative questions. This reference covers the full clinical picture: tumor biology and classification, FIGO staging, diagnostics, cytoreductive surgery, chemotherapy regimens, PARP inhibitors, ascites management, and the psychosocial dimensions of a disease that often strikes women in middle age.

Use this alongside the oncology nursing reference for general chemotherapy safety, hazardous drug handling, and oncologic emergency frameworks. BRCA1/2 genetics overlap with breast cancer nursing.

Tumor types and classification

Ovarian cancer is not a single disease. Three distinct tissue origins produce tumors with different presentations, tumor markers, and treatment responses.

Type	Frequency	Tumor marker	Typical patient	Key nursing note
Epithelial (serous, mucinous, endometrioid, clear cell)	~90% of ovarian cancers	CA-125 (especially serous); CEA elevated in mucinous	Postmenopausal women, age 55–65; BRCA carriers younger	High-grade serous is most common and most lethal; presents at advanced stage; responds to platinum-taxane chemo; PARP inhibitors used for BRCA-mutated/HRD-positive tumors
Germ cell (dysgerminoma, immature teratoma, yolk sac tumor)	~5% of ovarian cancers	AFP (yolk sac); beta-hCG (dysgerminoma); LDH (dysgerminoma)	Children and young women (teens–30s)	Often unilateral — fertility-sparing surgery is a priority; BEP chemotherapy (bleomycin, etoposide, cisplatin); highly chemosensitive with good prognosis
Sex cord-stromal (granulosa cell, Sertoli-Leydig)	~5% of ovarian cancers	Inhibin B; estradiol (granulosa cell); testosterone (Sertoli-Leydig)	Broad age range; granulosa cell = peri/postmenopausal; Sertoli-Leydig = younger women	Granulosa cell tumors produce estrogen → endometrial hyperplasia/cancer risk; Sertoli-Leydig tumors produce androgens → virilization (hirsutism, voice changes, clitoral enlargement); late recurrences possible (10–20 years)

NCLEX tip: AFP and beta-hCG elevation in an ovarian mass in a young woman points to a germ cell tumor, not epithelial ovarian cancer. Know which marker goes with which tumor type.

Pathophysiology and risk factors

Epithelial ovarian cancer: what drives it

High-grade serous ovarian carcinoma (HGSOC) — the dominant histotype — is now understood to originate largely from the fimbriated end of the fallopian tube, not the ovary surface itself. This has clinical implications: prophylactic salpingo-oophorectomy (removal of both tubes and ovaries) dramatically reduces risk, and there is ongoing research into whether salpingectomy alone might serve as a risk-reduction strategy in the general population.

At the molecular level, HGSOC is defined by near-universal TP53 mutations and a high rate of homologous recombination deficiency (HRD) — the DNA repair defect that makes BRCA-mutated and some non-BRCA tumors exquisitely sensitive to PARP inhibitors.

Hereditary risk: BRCA1, BRCA2, and Lynch syndrome

BRCA1 mutations carry a lifetime ovarian cancer risk of approximately 40–60%, compared with 1.3% in the general population. BRCA1-associated ovarian cancers tend to present younger (average age ~50) and are predominantly high-grade serous.

BRCA2 mutations carry a somewhat lower ovarian cancer risk (~10–20% lifetime). BRCA2 is more strongly associated with breast cancer risk than BRCA1. See breast cancer nursing for the full BRCA genetics framework.

Lynch syndrome (mismatch repair defects: MLH1, MSH2, MSH6, PMS2) increases endometrial cancer risk most substantially, but also elevates ovarian cancer risk, particularly the endometrioid and clear cell histotypes.

NCLEX tip: BRCA1 = higher ovarian cancer risk (~40–60%); BRCA2 = higher breast cancer risk relative to ovarian. Prophylactic salpingo-oophorectomy reduces ovarian cancer risk by 80–90% in BRCA carriers. Timing: BRCA1 carriers at age 35–40; BRCA2 carriers at age 40–45 (after childbearing is complete).

Other risk factors and protective factors

Risk factors:

Nulliparity and infertility (more ovulatory cycles = more surface epithelial repair = more mutation risk)
Endometriosis (particularly associated with endometrioid and clear cell histotypes)
Hormone replacement therapy (estrogen alone, prolonged use)
Increasing age — incidence rises sharply after menopause
Personal history of breast cancer
First-degree family history of ovarian or breast cancer

Protective factors:

Oral contraceptive pills (OCPs): 5+ years of use reduces lifetime risk by ~50%; protection persists for decades after stopping
Breastfeeding: each year of breastfeeding reduces risk modestly
Tubal ligation: reduces risk by ~30%
Salpingectomy at time of other pelvic surgery is now recommended as an opportunistic risk-reduction strategy

Clinical presentation: why diagnosis is delayed

Ovarian cancer is not truly asymptomatic. Studies show that most women with ovarian cancer report symptoms for months before diagnosis — the problem is that the symptoms overlap completely with common benign conditions.

Classic presenting symptoms:

Abdominal bloating or distension
Pelvic pressure or pain
Early satiety — feeling full quickly when eating
Urinary urgency or frequency (from pelvic mass pressure)
Changes in bowel habits
Fatigue

The Ovarian Cancer National Alliance recommends that any of these symptoms occurring more than 12 times per month, representing a change from baseline, should prompt evaluation.

Advanced disease findings:

Ascites — accumulation of fluid in the peritoneal cavity; may be massive, causing significant abdominal distension, dyspnea from diaphragmatic elevation, and malnutrition from protein loss
Pleural effusion — particularly right-sided; can impair respiration
Bowel obstruction — from peritoneal carcinomatosis involving the bowel serosa
Cachexia and weight loss
Palpable omental cake — a thickened, nodular omentum palpable on abdominal exam in advanced disease

Diagnostics and tumor markers

CA-125

CA-125 is the most important tumor marker in ovarian cancer management. Nursing students must understand what it does and does not do.

CA-125 IS used for:

Monitoring treatment response during chemotherapy
Surveillance after treatment (detecting recurrence)
Risk stratification (combined with other tools) in women with a pelvic mass

CA-125 is NOT a reliable screening test because:

Specificity is too low — many benign conditions elevate CA-125: endometriosis, fibroids, pelvic inflammatory disease, liver disease, pregnancy, even menstruation
Sensitivity for early-stage ovarian cancer is also poor (Stage I disease may not elevate CA-125)
Large randomized trials (UKCTOCS) have not shown mortality benefit from CA-125 screening in the general population

NCLEX tip: CA-125 is a monitoring/surveillance marker, NOT a diagnostic screening test. If an NCLEX question asks about ovarian cancer screening, the correct answer is that there is no reliable screening test for the general population.

ROMA score

The Risk of Ovarian Malignancy Algorithm (ROMA) combines:

CA-125 level
HE4 (human epididymis protein 4 — a second ovarian cancer marker)
Menopausal status

ROMA generates a percentage risk score for epithelial ovarian cancer in women presenting with a pelvic mass. It is used to guide surgical referral (gynecologic oncologist vs general gynecologist) — not population screening.

Imaging

Transvaginal ultrasound (TVUS): First-line imaging for a pelvic mass. Features raising concern: solid components, papillary projections, internal septations, ascites, bilateral masses.
CT scan of abdomen and pelvis: Standard for staging workup — identifies peritoneal implants, lymphadenopathy, liver/lung involvement, and assesses surgical feasibility.
MRI: May further characterize indeterminate pelvic masses.
PET-CT: Not routine for initial staging; sometimes used to evaluate recurrence.

Surgical staging

Definitive diagnosis and staging require surgery (FIGO staging is surgical). Biopsy of an ovarian mass is generally avoided before surgery because of the risk of rupturing the cyst and upstaging the disease. The standard approach is exploratory laparotomy with complete surgical staging.

FIGO staging quick reference

Stage	Description	5-year survival (approx.)	Nursing implication
Stage I	Confined to one or both ovaries/fallopian tubes; no peritoneal spread	~90%	Surgery alone may be curative for low-grade Stage IA; fertility-sparing surgery possible in select young patients; close surveillance required post-treatment
Stage II	Involves one or both ovaries/tubes with pelvic extension (uterus, bladder, rectum, other pelvic organs)	~70–75%	Adjuvant chemotherapy standard; patient education on 6 cycles paclitaxel + carboplatin; assess for surgical menopause symptoms if bilateral oophorectomy performed
Stage III	Peritoneal implants beyond the pelvis and/or retroperitoneal (pelvic/para-aortic) lymph node metastases; most common at diagnosis	~30–45%	Major debulking surgery — may include bowel resection, splenectomy, diaphragmatic stripping; post-op monitoring for ileus, DVT, pulmonary embolism; extensive patient education about recurrence patterns
Stage IV	Distant metastases beyond the peritoneal cavity: liver parenchymal mets, lung/pleural mets, inguinal lymph nodes, other distant organs	~15–20%	Neoadjuvant chemotherapy often used before surgery (interval debulking); malignant pleural effusion may require thoracentesis; ascites management; goals-of-care discussion appropriate; palliative care referral

NCLEX tip: Most ovarian cancer patients (approximately 75%) present at Stage III or IV. The late presentation is attributable to the vague nature of early symptoms combined with the absence of a reliable screening test.

Treatment overview

Primary debulking surgery (cytoreductive surgery)

The cornerstone of ovarian cancer treatment is cytoreductive surgery — surgical removal of as much tumor as possible before or alongside chemotherapy. The goal is optimal cytoreduction, defined as ≤1 cm of residual disease remaining anywhere in the abdomen after surgery.

Why residual disease matters: Optimal cytoreduction is the single strongest surgical predictor of survival. A patient with Stage III disease who is optimally debulked has significantly better outcomes than a patient with larger residual disease — independent of stage. This is a key NCLEX concept.

What debulking surgery may include:

Total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO)
Omentectomy (the omentum is a primary site of peritoneal spread)
Peritoneal stripping
Pelvic and para-aortic lymph node dissection
Bowel resection (with or without colostomy)
Splenectomy
Diaphragmatic stripping or resection
Appendectomy

The scope of this surgery is enormous. Nurses must prepare patients for the possibility of bowel resection and temporary colostomy, and for a prolonged recovery.

Neoadjuvant chemotherapy and interval debulking

For patients with very advanced disease (Stage IV, massive peritoneal disease, poor performance status), primary debulking may not be feasible. These patients receive neoadjuvant chemotherapy (NACT) — typically 3–4 cycles of paclitaxel/carboplatin — followed by interval debulking surgery, then additional chemotherapy.

NACT reduces surgical morbidity and may allow a previously inoperable patient to achieve optimal cytoreduction. It is equivalent to primary debulking in overall survival for Stage IIIC–IV disease.

Chemotherapy: paclitaxel and carboplatin

First-line chemotherapy for advanced ovarian cancer is the paclitaxel + carboplatin (TC) doublet, typically given IV every 3 weeks for 6 cycles.

Bevacizumab (anti-VEGF monoclonal antibody) is commonly added to first-line chemotherapy and continued as maintenance in Stage III–IV patients. Key nursing concern: hypertension and delayed wound healing — bevacizumab must be withheld for 4–6 weeks perioperatively.

Platinum-sensitive vs platinum-resistant disease

Recurrence classification drives second-line treatment decisions:

Platinum-sensitive: Recurrence >6 months after completing platinum-based chemotherapy. Re-treatment with platinum doublet remains effective; may also receive bevacizumab or PARP inhibitor maintenance.
Platinum-resistant: Recurrence <6 months after platinum therapy. Platinum retreatment is unlikely to help. Second-line non-platinum agents used: liposomal doxorubicin (Doxil), topotecan, gemcitabine, or weekly paclitaxel.

NCLEX tip: Platinum-sensitive = relapse >6 months after platinum; platinum-resistant = relapse <6 months after platinum. This classification directly determines whether the patient will receive a platinum agent again.

PARP inhibitors (maintenance therapy)

PARP inhibitors represent a paradigm shift in ovarian cancer. They are used as maintenance therapy — continued after chemotherapy response to delay recurrence — not as acute treatment.

Available PARP inhibitors in ovarian cancer:

Olaparib (Lynparza): First PARP inhibitor approved; requires either BRCA1/2 mutation (germline or somatic) or HRD-positive tumor biomarker for some indications
Niraparib (Zejula): Does not require BRCA mutation — approved for all patients with advanced ovarian cancer in platinum-sensitive recurrence regardless of BRCA status
Rucaparib (Rubraca): Also BRCA-mutation or HRD-dependent for ovarian cancer indications

Mechanism: PARP enzymes repair single-strand DNA breaks. BRCA-mutated tumors cannot repair double-strand breaks via homologous recombination. PARP inhibition in these tumors leads to lethal DNA damage accumulation — synthetic lethality.

Chemotherapy nursing considerations

Drug	Mechanism	Key nursing considerations	Major toxicities
Paclitaxel (Taxol)	Taxane — stabilizes microtubules, prevents cell division	Premedication required before every infusion: dexamethasone (PO 12h and 6h before, OR IV 30 min before), diphenhydramine 50 mg IV, H2 blocker (famotidine or ranitidine) — prevents hypersensitivity reaction (HSR). Infuse through non-DEHP tubing. Run initial infusion slowly; monitor vitals every 15 min first 30 min. HSR signs: flushing, urticaria, hypotension, dyspnea, chest tightness — typically occur within first 10 min of first 2 cycles. Stop infusion immediately; have epinephrine, diphenhydramine, corticosteroids at bedside.	Hypersensitivity reaction (HSR, up to 10% without premedication), peripheral neuropathy (dose-limiting, cumulative), myelosuppression, alopecia, myalgia/arthralgia (3–5 days post-infusion), bradycardia
Carboplatin (Paraplatin)	Platinum analog — cross-links DNA, disrupts replication	Monitor cumulative platinum exposure — allergic reactions increase with each cycle (highest risk after cycle 4–6 and with re-treatment in platinum-sensitive recurrence). Pre-assess for hypersensitivity symptoms before each infusion. Calculate AUC-based dosing using Calvert formula (requires serum creatinine/GFR). Monitor renal function before each cycle. Carboplatin is less nephrotoxic than cisplatin but still requires renal monitoring — see AKI nursing for nephrotoxicity principles.	Myelosuppression (nadir day 21, carboplatin is more myelosuppressive than cisplatin), allergic reaction (cumulative risk), nausea/vomiting (less severe than cisplatin), nephrotoxicity (milder than cisplatin), ototoxicity (rare)
Bevacizumab (Avastin)	Anti-VEGF monoclonal antibody — inhibits angiogenesis	Do NOT administer within 4–6 weeks of surgery (impairs wound healing; risk of anastomotic dehiscence). Monitor BP every infusion — hypertension is dose-dependent and may require antihypertensive therapy. Watch for proteinuria (dipstick each cycle). Assess for GI perforation symptoms (abdominal pain, rigidity, fever) — rare but life-threatening, particularly in patients with prior bowel resection or carcinomatosis.	Hypertension, proteinuria, impaired wound healing, thromboembolic events (arterial more concerning), GI perforation (rare, serious), fistula formation, hemorrhage
Olaparib/niraparib (PARP inhibitors)	PARP enzyme inhibition — synthetic lethality in HRD-positive/BRCA-mutated tumors	Oral agents (taken at home) — teach patients rigorously. Monitor CBC at baseline, monthly for 12 months, then periodically — cytopenias are common. Hold for platelets <50,000/µL. Niraparib: dose-reduce for thrombocytopenia (initial 100 mg dose reduction). Olaparib: requires BRCA mutation or HRD biomarker confirmation before prescribing. Teach nausea management (take with food, antiemetics available). Fatigue is prominent — counsel on energy conservation. MDS/AML risk is rare but real with prolonged use — report persistent cytopenias.	Nausea/vomiting, fatigue, anemia, thrombocytopenia, neutropenia, MDS/AML (rare, <1.5%), headache, dyspnea, elevated creatinine (niraparib — typically non-progressive)

Post-operative nursing care after debulking surgery

Cytoreductive surgery for advanced ovarian cancer is among the most extensive abdominal procedures in gynecologic oncology. Nursing priorities in the immediate post-operative period are substantial.

Airway and respiratory monitoring

Patients who have undergone diaphragmatic stripping are at high risk for pleural effusion and pneumothorax in the immediate post-operative period. Assess breath sounds every 2 hours. A chest tube may be in place if the diaphragm was entered. Incentive spirometry and early ambulation are essential.

Ileus prevention and management

Bowel resection (which may be performed to achieve optimal cytoreduction) significantly increases ileus risk. Nursing assessment:

Auscultate bowel sounds every 4 hours
Monitor for return of flatus and stool
NPO until bowel function returns; advance diet as directed
Signs of bowel obstruction: nausea, vomiting, absent bowel sounds, abdominal distension, failure to pass flatus — notify provider immediately

NCLEX tip: Post-debulking bowel obstruction is a serious complication requiring prompt assessment. The nurse’s role is recognizing the signs (absent bowel sounds, N/V, distension) and escalating — not managing independently.

DVT prophylaxis

Patients with ovarian cancer face compounding VTE risk: malignancy, major abdominal surgery, prolonged immobility, and peritoneal disease all independently elevate risk. Standard prophylaxis includes sequential compression devices (SCDs) intraoperatively and postoperatively, pharmacologic anticoagulation (low-molecular-weight heparin or unfractionated heparin) as soon as hemostasis allows, and early ambulation.

See DVT nursing for full deep vein thrombosis assessment and nursing care.

Wound care and stoma care

If bowel resection with colostomy was performed, the nurse assesses the stoma:

Color: should be beefy red — dark purple or black indicates ischemia (notify surgeon immediately)
Edema: expected in the first 2–3 days, resolves
Output: type depends on stoma location (liquid from ileostomy, semi-formed from descending colostomy)
Skin around the stoma: protect from stomal effluent, especially ileostomy (high enzymatic content)

Pain management

Epidural analgesia or IV PCA is standard immediately post-operatively. Assess pain score, sedation level, and respiratory rate. Transition to oral agents as tolerated. NSAIDs are often avoided in the first 72 hours post-major surgery.

Anemia from surgery and chemotherapy

Significant intraoperative blood loss during debulking is common. Post-operative anemia is nearly universal. Monitor CBC; transfusion thresholds are typically Hgb <7 g/dL or <8 g/dL with symptoms. Chemotherapy-induced anemia develops over subsequent cycles — see anemia nursing reference for erythropoiesis-stimulating agent (ESA) considerations.

Ascites management

Malignant ascites in ovarian cancer results from peritoneal implants disrupting lymphatic drainage and producing peritoneal fluid directly. It is both a diagnostic sign and a major source of symptom burden.

Assessment

Abdominal girth measurement (document site of measurement for consistency)
Daily weights
Respiratory status — massive ascites elevates the diaphragm, reducing lung expansion
Nutritional status — ascites protein loss drives hypoalbuminemia, which worsens peripheral edema in a self-reinforcing cycle

Paracentesis nursing care

When ascites is symptomatic (dyspnea, abdominal discomfort, early satiety), large-volume paracentesis provides relief.

Pre-procedure:

Verify consent and recent coagulation studies/platelet count
Position: sitting at edge of bed or semi-recumbent
Baseline vital signs and abdominal girth
Mark site (ultrasound-guided preferred)

During procedure:

Monitor vital signs every 15 minutes
Assess for hypotension — rapid fluid removal can shift intravascular volume

Post-procedure:

Monitor BP and HR for 1–2 hours; orthostatic hypotension is common
Monitor serum albumin — fluid removal depletes protein; albumin infusion (6–8 g per liter removed) may be ordered for large-volume paracentesis
Document drainage volume and characteristics (straw-colored is typical; bloody may indicate tumor bleeding)
Ascites reaccumulates rapidly with active peritoneal disease — educate patient that repeat procedures are often needed

NCLEX tips:

Post-paracentesis: monitor BP, HR, and serum albumin; reaccumulation is common and expected with active malignancy
Ascites protein loss → hypoalbuminemia → peripheral edema (third spacing due to reduced oncotic pressure)

See cirrhosis nursing for the physiology of ascites formation (similar mechanisms apply in malignant ascites).

Gynecologic cancer NCLEX differentiation table

Feature	Ovarian cancer	Cervical cancer	Endometrial cancer
Primary risk factor	BRCA1/2 mutation, family history, nulliparity	HPV infection (especially types 16 and 18) — in virtually all cases	Unopposed estrogen exposure (obesity, anovulation, tamoxifen use, PCOS)
Classic presentation	Vague bloating, pelvic pressure, early satiety — often late-stage at diagnosis	Postcoital bleeding, intermenstrual bleeding, watery vaginal discharge	Postmenopausal vaginal bleeding (90% of cases have this as first symptom — diagnosed early)
Tumor marker	CA-125 (surveillance/monitoring only); HE4	No reliable serum tumor marker; SCC-Ag in some squamous cases	CA-125 can be mildly elevated; not clinically relied upon for monitoring
Screening	No reliable screening test for general population	Pap smear + HPV co-testing (recommended every 5 years ages 30–65)	No routine screening; postmenopausal bleeding triggers endometrial biopsy
Staging system	FIGO (surgical staging)	FIGO (clinical staging — may be done without surgery in low-resource settings)	FIGO (surgical staging)
Dominant histology	Epithelial (high-grade serous ~70%)	Squamous cell carcinoma (~70%); adenocarcinoma (~25%)	Endometrioid adenocarcinoma (~80%)
Primary treatment	Cytoreductive surgery + paclitaxel/carboplatin; PARP inhibitor maintenance	Radiation + concurrent cisplatin (definitive); radical hysterectomy (early stage)	Total hysterectomy + bilateral salpingo-oophorectomy ± pelvic radiation
Key NCLEX concept	CA-125 is NOT a screening test; optimal cytoreduction = best survival predictor; paclitaxel premedication	HPV vaccination prevents ~90% of cervical cancers; Pap smear timing after LEEP	Any postmenopausal vaginal bleeding requires evaluation — do not dismiss; good prognosis because presents early

Fertility preservation and surgical menopause

Fertility preservation counseling

For women of reproductive age diagnosed with ovarian cancer — particularly germ cell and early-stage epithelial tumors — fertility preservation is an urgent conversation that must happen before treatment begins.

Fertility-sparing surgery (unilateral salpingo-oophorectomy with preservation of the contralateral ovary and uterus) is appropriate for:

Stage IA, grade 1 epithelial cancer in women who want to preserve fertility
Germ cell tumors regardless of stage (most are unilateral; BEP chemotherapy is compatible with fertility preservation)

Nursing role: Identify young patients early, ensure oncology and reproductive endocrinology/fertility specialist consultation happens before surgery or chemotherapy starts. Oocyte or embryo cryopreservation requires 10–14 days before chemotherapy. This window is narrow — early referral is critical.

Surgical menopause

For women who have not yet reached natural menopause, bilateral oophorectomy causes immediate surgical menopause. Symptoms are often more severe than natural menopause because of the abrupt estrogen withdrawal:

Vasomotor symptoms (hot flashes, night sweats)
Genitourinary syndrome (vaginal dryness, dyspareunia, urinary urgency)
Mood changes, cognitive symptoms
Accelerated bone loss (refer to primary care for bone density monitoring)
Increased cardiovascular risk long-term

Hormone replacement therapy (HRT): Generally contraindicated in women with hormone-sensitive ovarian cancer (such as endometrioid or clear cell histotypes, or granulosa cell tumors). For high-grade serous ovarian cancer survivors, short-term low-dose HRT may be considered for severe vasomotor symptoms — but this is an individualized decision made with oncology. Nurses should not assume HRT is always off-limits or always safe; the conversation belongs with the treating oncologist.

Psychosocial care

Ovarian cancer carries a substantial psychosocial burden. The combination of late-stage diagnosis, difficult treatment, high recurrence rates, and treatment-induced menopause in younger women creates complex emotional needs.

Key nursing priorities:

Body image: Surgical changes (colostomy, hair loss from paclitaxel, weight changes from steroids and ascites), treatment-induced menopause, and sexual dysfunction all affect body image and intimate relationships. Normalize these concerns and facilitate referrals to social work, sexual health specialists, and support groups.

Existential distress: Many patients receive a Stage III or IV diagnosis with a 5-year survival rate they can find online. Anxiety about prognosis, recurrence, and legacy is common. Nurses are often the consistent presence who can open these conversations — a non-anxious, compassionate bedside manner is therapeutic in itself.

Genetic counseling implications: A new ovarian cancer diagnosis often triggers cascade testing in first-degree relatives. Patients may carry guilt about transmitting BRCA mutations to children or siblings. Genetic counseling referral — for the patient and optionally for family members — is standard of care.

Caregiver burden: Partners and family members take on significant caregiving roles. Include them in education and facilitate caregiver support resources.

NCLEX high-yield points: ovarian cancer

CA-125 is a monitoring and surveillance marker, not a diagnostic screening test. Elevated CA-125 alone does not diagnose ovarian cancer; many benign conditions elevate it.
No reliable screening test exists for ovarian cancer in the general population. Annual pelvic exam does not reliably detect early ovarian cancer.
Most patients present at Stage III–IV (~75%) because early symptoms are vague and there is no effective screening.
BRCA1 = higher ovarian cancer risk (~40–60% lifetime); BRCA2 = higher breast cancer risk relative to ovarian. Both significantly elevate ovarian cancer risk compared with the general population.
Prophylactic salpingo-oophorectomy reduces ovarian cancer risk by 80–90% in BRCA carriers. Timing: BRCA1 = age 35–40; BRCA2 = age 40–45.
Optimal cytoreduction (≤1 cm residual disease) is the strongest surgical predictor of survival — more important than stage alone in determining outcome.
Debulking surgery may include bowel resection, splenectomy, and diaphragmatic stripping. Prepare patients for this scope of surgery, including the possibility of a temporary colostomy.
Paclitaxel requires premedication before every infusion: dexamethasone, diphenhydramine, and an H2 blocker. Hypersensitivity reactions are most likely during the first 2 cycles.
Paclitaxel HSR: Stop infusion immediately. Symptoms — flushing, urticaria, hypotension, dyspnea — typically occur within the first 10 minutes. Have epinephrine, diphenhydramine, and corticosteroids at bedside.
Carboplatin allergy risk is cumulative. Re-assess for hypersensitivity before each cycle, and particularly before retreatment in platinum-sensitive recurrence. Carboplatin is dosed by AUC using the Calvert formula, which requires current renal function.
PARP inhibitors (olaparib, niraparib): Hold for platelets <50,000/µL. Monitor CBC monthly for the first year. Teach patients about fatigue, nausea, and the rare risk of MDS/AML with prolonged use.
Olaparib requires BRCA mutation (germline or somatic) or HRD-positive biomarker for most ovarian cancer indications. Niraparib does not require BRCA mutation — approved for all-comers in platinum-sensitive recurrence.
Platinum-sensitive = recurrence >6 months after completing platinum therapy. Platinum-resistant = recurrence <6 months after platinum. This determines whether the patient can receive a platinum agent again.
Bevacizumab must be withheld 4–6 weeks perioperatively. VEGF inhibition impairs wound healing and increases anastomotic leak risk.
Signs of post-debulking bowel obstruction: nausea, vomiting, absent bowel sounds, abdominal distension, failure to pass flatus. Notify provider immediately.
ROMA score combines CA-125 + HE4 + menopausal status to risk-stratify a pelvic mass. Used for surgical referral decisions, not population screening.
Post-paracentesis: monitor BP and HR for orthostatic hypotension; check serum albumin; ascites typically reaccumulates with active peritoneal malignancy.
Surgical menopause from bilateral oophorectomy: immediate, severe vasomotor and genitourinary symptoms. HRT eligibility is tumor-type dependent — discuss with oncology before prescribing.
Fertility preservation referral must happen before surgery or chemotherapy starts in reproductive-age patients. The window for oocyte/embryo cryopreservation is 10–14 days — early identification and referral are a nursing priority.
Germ cell tumors present in young women/adolescents. AFP and beta-hCG are the relevant markers (not CA-125). BEP chemotherapy. Fertility-sparing surgery is the standard approach.

Summary: essential ovarian cancer nursing concepts

Ovarian cancer is a disease of late presentation, extensive surgical intervention, and prolonged systemic treatment. The nursing role spans the entire trajectory: genetic risk counseling and fertility preservation at diagnosis, perioperative management of one of the most complex abdominal surgeries in gynecology, chemotherapy administration with meticulous hypersensitivity monitoring, oral PARP inhibitor education and toxicity surveillance, and ascites management across a disease course that often spans years.

For NCLEX, master three domains: (1) what CA-125 is and is not; (2) the paclitaxel premedication and HSR protocol; and (3) the post-debulking complication set — ileus, bowel obstruction, DVT, wound care. Everything else builds from these foundations.

For clinical practice, the deeper skill is recognizing the psychosocial weight carried by patients who often receive a Stage III diagnosis after months of dismissed symptoms. That recognition, translated into unhurried assessment conversations, appropriate referrals, and consistent presence, is what distinguishes competent nursing from excellent nursing.

Sources: American Cancer Society ovarian cancer statistics; NCCN Clinical Practice Guidelines in Oncology — Ovarian Cancer (current edition); NIH National Cancer Institute ovarian cancer PDQ; Society of Gynecologic Oncology (SGO) guidelines; FDA prescribing information for paclitaxel, carboplatin, bevacizumab, olaparib (Lynparza), niraparib (Zejula); Ovarian Cancer Research Alliance clinical resources; Gynecologic Oncology (journal) PARP inhibitor trial data (SOLO-1, PRIMA, ARIEL3); FIGO 2023 ovarian cancer staging system.